Literature DB >> 15536161

Testicular anti-mullerian hormone secretion is stimulated by recombinant human FSH in patients with congenital hypogonadotropic hypogonadism.

Jacques Young1, Philippe Chanson, Sylvie Salenave, Michèle Noël, Sylvie Brailly, Martín O'Flaherty, Gilbert Schaison, Rodolfo Rey.   

Abstract

Serum anti-Mullerian hormone (AMH), a prepubertal Sertoli cell marker, declines during puberty as an early sign of testicular testosterone (T) production. When T synthesis or action is impaired, serum AMH is abnormally high in the first months after birth and at puberty but normal between these two periods. We postulated that FSH might be responsible for AMH up-regulation in the absence of androgen inhibition. To test this hypothesis, we administered recombinant human (rh) FSH to eight patients aged from 18-31 yr with untreated congenital hypogonadotropic hypogonadism. This situation is ideal to study the effect of FSH on AMH production because it avoids interference by endogenous gonadotropins and T. The patients received daily sc injections of 150 IU rhFSH for 1 month, followed in seven of them by a combined treatment of rhFSH plus human chorionic gonadotropin (hCG; 1500 UI im, twice a week) for 2 months. Gonadotropins, T, AMH, and inhibin B were measured in plasma before treatment every 10 d during rhFSH treatment and every month during combined rhFSH and hCG treatments. All hormones were at prepubertal levels before treatment. Although LH and T did not vary, AMH and inhibin B levels gradually increased after 20 d of FSH administration. However, in contrast to rhFSH alone, the combined rhFSH plus hCG stimulation of the testis dramatically suppresses the secretion of AMH and induced a modest but significant reduction of circulating inhibin B levels. We conclude that FSH stimulates AMH production in the testis when it is at a prepubertal stage. In addition, the decrease of serum AMH during combined rhFSH and hCG testicular stimulation is in agreement with the concept that during pubertal development and in adult life, the suppressive effect of LH-driven testicular androgens outweighs the stimulating effect of FSH on AMH production by Sertoli cells. Finally, the hCG-induced decrease in inhibin B suggests that in humans, as previously demonstrated in monkeys, testicular T is also able to inhibit inhibin B secretion.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15536161     DOI: 10.1210/jc.2004-0542

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  32 in total

Review 1.  Neonatal gonadotropin therapy in male congenital hypogonadotropic hypogonadism.

Authors:  Claire Bouvattier; Luigi Maione; Jérôme Bouligand; Catherine Dodé; Anne Guiochon-Mantel; Jacques Young
Journal:  Nat Rev Endocrinol       Date:  2011-10-18       Impact factor: 43.330

2.  Expression of FSH and its co-localization with FSH receptor and GnRH receptor in rat cerebellar cortex.

Authors:  Chenyu Chu; Jing'an Zhou; Yaqun Zhao; Ce Liu; Pengfei Chang; Qing Zhou; Li Zhao; Weiquan Huang
Journal:  J Mol Histol       Date:  2012-09-13       Impact factor: 2.611

Review 3.  Evaluation of testicular function in prepubertal children.

Authors:  Rosita A Condorelli; Rossella Cannarella; Aldo E Calogero; Sandro La Vignera
Journal:  Endocrine       Date:  2018-07-07       Impact factor: 3.633

4.  Pubertal induction and transition to adult sex hormone replacement in patients with congenital pituitary or gonadal reproductive hormone deficiency: an Endo-ERN clinical practice guideline.

Authors:  A Nordenström; S F Ahmed; E van den Akker; J Blair; M Bonomi; C Brachet; L H A Broersen; H L Claahsen-van der Grinten; A B Dessens; A Gawlik; C H Gravholt; A Juul; C Krausz; T Raivio; A Smyth; P Touraine; D Vitali; O M Dekkers
Journal:  Eur J Endocrinol       Date:  2022-04-21       Impact factor: 6.558

5.  Lack of androgen receptor expression in Sertoli cells accounts for the absence of anti-Mullerian hormone repression during early human testis development.

Authors:  Kahina Boukari; Geri Meduri; Sylvie Brailly-Tabard; Jean Guibourdenche; Maria Luisa Ciampi; Nathalie Massin; Laetitia Martinerie; Jean-Yves Picard; Rodolfo Rey; Marc Lombès; Jacques Young
Journal:  J Clin Endocrinol Metab       Date:  2009-03-10       Impact factor: 5.958

6.  Relationship between 17-hydroxyprogesterone responses to human chorionic gonadotropin and markers of ovarian follicle morphology in women with polycystic ovary syndrome.

Authors:  Kevin H Maas; Sandy S Chuan; Heidi Cook-Andersen; H Irene Su; A Duleba; R Jeffrey Chang
Journal:  J Clin Endocrinol Metab       Date:  2015-01       Impact factor: 5.958

7.  Serum insulin-like factor 3 is highly correlated with intratesticular testosterone in normal men with acute, experimental gonadotropin deficiency stimulated with low-dose human chorionic gonadotropin: a randomized, controlled trial.

Authors:  Mara Y Roth; Kat Lin; Katrine Bay; John K Amory; Bradley D Anawalt; Alvin M Matsumoto; Brett T Marck; William J Bremner; Stephanie T Page
Journal:  Fertil Steril       Date:  2012-10-03       Impact factor: 7.329

8.  Trial of recombinant follicle-stimulating hormone pretreatment for GnRH-induced fertility in patients with congenital hypogonadotropic hypogonadism.

Authors:  Andrew A Dwyer; Gerasimos P Sykiotis; Frances J Hayes; Paul A Boepple; Hang Lee; Kevin R Loughlin; Martin Dym; Patrick M Sluss; William F Crowley; Nelly Pitteloud
Journal:  J Clin Endocrinol Metab       Date:  2013-09-13       Impact factor: 5.958

Review 9.  Biomarkers of chemotherapy-induced testicular damage.

Authors:  Edward Dere; Linnea M Anderson; Kathleen Hwang; Kim Boekelheide
Journal:  Fertil Steril       Date:  2013-11       Impact factor: 7.329

10.  Adverse pathophysiological influence of early testosterone therapy on the testes of boys with higher grade sex chromosome aneuploidies (HGAs): a retrospective, cross-sectional study.

Authors:  M Spaziani; C Tarantino; C Pozza; A Anzuini; F Panimolle; G Papi; D Gianfrilli; A Lenzi; A F Radicioni
Journal:  J Endocrinol Invest       Date:  2020-10-24       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.